Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Biologics Contract Development Market by Source (Microbial, Mammalian, Others), by Product Service (Cell Line Development, Process Development, Others) and by Disease Indication (Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A13187

Pages: NA

Charts: NA

Tables: NA

Biologics Contract Development Market Overview 2030

Biologics are genetically engineered proteins which are originated from genes of human. Biologic drugs target the specific parts of the human immune system. Biologics are completely different from chemically synthesized drugs. There is wide range of biologic products include blood components, somatic cells, recombinant gene therapies, vaccine, and allergenic. Biologics are constituted as nucleic acid, proteins, and tissue from living organisms. This products are isolated from sources such as animal, human, and microbes with the help of biotechnological methods. This product is very sensitive to contamination thus, biologics contract development exhibits high demand from pharmaceutical companies.

COVID-19 Impact Analysis             

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

There has been an increase in the demand for medical supplies to take care of infected population. Respiratory support devices such as atomizers, life-support machines, oxygen generators, and monitors are among the majorly used medical devices in primary clinical treatment. Moreover, COVID-19 has led to a huge surge in demand for medical supplies such as personal protective equipment including masks, gloves, and protective eyeglasses. There is an increase in the need for medical supplies, both from healthcare professionals and civil population for precautionary measures, owing to the rise in number of COVID-19 cases worldwide. Manufacturers of these products have a chance to capitalize this increased demand for medical supplies to ensure adequate and continuous supply of personal protective equipment in the market. Therefore, COVID-19 is expected to have a significant impact on the biologics contract development market.

Top Impacting Factors

  • Increase in number of drug development procedures by pharmaceutical companies, surge in rate of drug approval by Food and Drug Administration,  surge in usage of targeted drug therapies, rise in demand for personalized medication, and increase in cases of chronic diseases are the major factors that drive the growth of the biologics contract development market.
  • In addition, increase in adoption of advanced technologies for biologic development, favourable environment for clinical trials in developing countries, surge in number of collaboration, contracts & mergers with local players to develop advance biologic products, and increase in demand for treatment of rare diseases are some factors that fuel the growth of the market.
  • However, high cost associated with biologics production methods and lack of awareness regarding use of these products restrain the growth of the biologics contract development market.
  • Contrarily, rise in development of greater manufacturing flexibility in biopharmaceutical sector are expected to offer lucrative opportunities for the expansion of the market.

Market Trends

New Product Launches to Flourish the Market

In 2021, Almac Group announced launch of biologics contract of testing and development solutions for expansion of their business. This expansion will help in development and testing of new biologics products.

In 2020, Lake Pharma In., announced launch of integrated chemistry and biologics services for streamlined antibody- drug conjugates development solutions for pharmaceutical and biotechnology sectors.

Key Benefits of the Report

  • This study presents the analytical depiction of biologics contract development market industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the biologics contract development market share.
  • The current market is quantitatively analyzed to highlight the biologics contract development market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the Biologics Contract Development Market Report       

  • Which are the leading players active in the biologics contract development market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What is "biologics contract development"?
  • What is "biologics contract development" market prediction in the future?
  • Who are the leading global players in the "biologics contract development" market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the "biologics contract development" market report?

 Key Market Segments

  • By Source
    • Microbial
    • Mammalian
    • Others
  • By Product Service
    • Cell Line Development
    • Process Development
    • Others
  • By Disease Indication
    • Oncology
    • Immunological Disorders
    • Cardiovascular Disorders
    • Hematological Disorders
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • LakePharma
  • STC Biologics, Inc.
  • AGC Biologics
  • Fujifilm Diosynth Biotechnologies
  • KBI Biopharma
  • Boehringer Ingelheim BioXcellence
  • Bionova Scientific
  • SE Thermo Fisher (Patheon)
  • WuXi Biologics
  • Abzena Ltd.
  • Genscript Biotech Corporation

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY SOURCE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Source

    • 4.2. Microbial

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Mammalian

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Others

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY PRODUCT SERVICE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Product Service

    • 5.2. Cell Line Development

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Process Development

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Others

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY DISEASE INDICATION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Disease Indication

    • 6.2. Oncology

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Immunological Disorders

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Cardiovascular Disorders

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Hematological Disorders

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

    • 6.6. Others

      • 6.6.1. Key Market Trends, Growth Factors and Opportunities

      • 6.6.2. Market Size and Forecast, By Region

      • 6.6.3. Market Share Analysis, By Country

  • CHAPTER 7: BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Source

      • 7.2.3. Market Size and Forecast, By Product Service

      • 7.2.4. Market Size and Forecast, By Disease Indication

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Biologics Contract Development Market

        • 7.2.6.1. Market Size and Forecast, By Source
        • 7.2.6.2. Market Size and Forecast, By Product Service
        • 7.2.6.3. Market Size and Forecast, By Disease Indication

      • 7.2.7. Canada Biologics Contract Development Market

        • 7.2.7.1. Market Size and Forecast, By Source
        • 7.2.7.2. Market Size and Forecast, By Product Service
        • 7.2.7.3. Market Size and Forecast, By Disease Indication

      • 7.2.8. Mexico Biologics Contract Development Market

        • 7.2.8.1. Market Size and Forecast, By Source
        • 7.2.8.2. Market Size and Forecast, By Product Service
        • 7.2.8.3. Market Size and Forecast, By Disease Indication

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Source

      • 7.3.3. Market Size and Forecast, By Product Service

      • 7.3.4. Market Size and Forecast, By Disease Indication

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Biologics Contract Development Market

        • 7.3.6.1. Market Size and Forecast, By Source
        • 7.3.6.2. Market Size and Forecast, By Product Service
        • 7.3.6.3. Market Size and Forecast, By Disease Indication

      • 7.3.7. Germany Biologics Contract Development Market

        • 7.3.7.1. Market Size and Forecast, By Source
        • 7.3.7.2. Market Size and Forecast, By Product Service
        • 7.3.7.3. Market Size and Forecast, By Disease Indication

      • 7.3.8. Italy Biologics Contract Development Market

        • 7.3.8.1. Market Size and Forecast, By Source
        • 7.3.8.2. Market Size and Forecast, By Product Service
        • 7.3.8.3. Market Size and Forecast, By Disease Indication

      • 7.3.9. Spain Biologics Contract Development Market

        • 7.3.9.1. Market Size and Forecast, By Source
        • 7.3.9.2. Market Size and Forecast, By Product Service
        • 7.3.9.3. Market Size and Forecast, By Disease Indication

      • 7.3.10. UK Biologics Contract Development Market

        • 7.3.10.1. Market Size and Forecast, By Source
        • 7.3.10.2. Market Size and Forecast, By Product Service
        • 7.3.10.3. Market Size and Forecast, By Disease Indication

      • 7.3.11. Russia Biologics Contract Development Market

        • 7.3.11.1. Market Size and Forecast, By Source
        • 7.3.11.2. Market Size and Forecast, By Product Service
        • 7.3.11.3. Market Size and Forecast, By Disease Indication

      • 7.3.12. Rest Of Europe Biologics Contract Development Market

        • 7.3.12.1. Market Size and Forecast, By Source
        • 7.3.12.2. Market Size and Forecast, By Product Service
        • 7.3.12.3. Market Size and Forecast, By Disease Indication

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Source

      • 7.4.3. Market Size and Forecast, By Product Service

      • 7.4.4. Market Size and Forecast, By Disease Indication

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Biologics Contract Development Market

        • 7.4.6.1. Market Size and Forecast, By Source
        • 7.4.6.2. Market Size and Forecast, By Product Service
        • 7.4.6.3. Market Size and Forecast, By Disease Indication

      • 7.4.7. Japan Biologics Contract Development Market

        • 7.4.7.1. Market Size and Forecast, By Source
        • 7.4.7.2. Market Size and Forecast, By Product Service
        • 7.4.7.3. Market Size and Forecast, By Disease Indication

      • 7.4.8. India Biologics Contract Development Market

        • 7.4.8.1. Market Size and Forecast, By Source
        • 7.4.8.2. Market Size and Forecast, By Product Service
        • 7.4.8.3. Market Size and Forecast, By Disease Indication

      • 7.4.9. South Korea Biologics Contract Development Market

        • 7.4.9.1. Market Size and Forecast, By Source
        • 7.4.9.2. Market Size and Forecast, By Product Service
        • 7.4.9.3. Market Size and Forecast, By Disease Indication

      • 7.4.10. Australia Biologics Contract Development Market

        • 7.4.10.1. Market Size and Forecast, By Source
        • 7.4.10.2. Market Size and Forecast, By Product Service
        • 7.4.10.3. Market Size and Forecast, By Disease Indication

      • 7.4.11. Thailand Biologics Contract Development Market

        • 7.4.11.1. Market Size and Forecast, By Source
        • 7.4.11.2. Market Size and Forecast, By Product Service
        • 7.4.11.3. Market Size and Forecast, By Disease Indication

      • 7.4.12. Malaysia Biologics Contract Development Market

        • 7.4.12.1. Market Size and Forecast, By Source
        • 7.4.12.2. Market Size and Forecast, By Product Service
        • 7.4.12.3. Market Size and Forecast, By Disease Indication

      • 7.4.13. Indonesia Biologics Contract Development Market

        • 7.4.13.1. Market Size and Forecast, By Source
        • 7.4.13.2. Market Size and Forecast, By Product Service
        • 7.4.13.3. Market Size and Forecast, By Disease Indication

      • 7.4.14. Rest of Asia Pacific Biologics Contract Development Market

        • 7.4.14.1. Market Size and Forecast, By Source
        • 7.4.14.2. Market Size and Forecast, By Product Service
        • 7.4.14.3. Market Size and Forecast, By Disease Indication

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Source

      • 7.5.3. Market Size and Forecast, By Product Service

      • 7.5.4. Market Size and Forecast, By Disease Indication

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Biologics Contract Development Market

        • 7.5.6.1. Market Size and Forecast, By Source
        • 7.5.6.2. Market Size and Forecast, By Product Service
        • 7.5.6.3. Market Size and Forecast, By Disease Indication

      • 7.5.7. South Africa Biologics Contract Development Market

        • 7.5.7.1. Market Size and Forecast, By Source
        • 7.5.7.2. Market Size and Forecast, By Product Service
        • 7.5.7.3. Market Size and Forecast, By Disease Indication

      • 7.5.8. Saudi Arabia Biologics Contract Development Market

        • 7.5.8.1. Market Size and Forecast, By Source
        • 7.5.8.2. Market Size and Forecast, By Product Service
        • 7.5.8.3. Market Size and Forecast, By Disease Indication

      • 7.5.9. UAE Biologics Contract Development Market

        • 7.5.9.1. Market Size and Forecast, By Source
        • 7.5.9.2. Market Size and Forecast, By Product Service
        • 7.5.9.3. Market Size and Forecast, By Disease Indication

      • 7.5.10. Argentina Biologics Contract Development Market

        • 7.5.10.1. Market Size and Forecast, By Source
        • 7.5.10.2. Market Size and Forecast, By Product Service
        • 7.5.10.3. Market Size and Forecast, By Disease Indication

      • 7.5.11. Rest of LAMEA Biologics Contract Development Market

        • 7.5.11.1. Market Size and Forecast, By Source
        • 7.5.11.2. Market Size and Forecast, By Product Service
        • 7.5.11.3. Market Size and Forecast, By Disease Indication

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. WuXi Biologics

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Abzena Ltd.

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Fujifilm Diosynth Biotechnologies

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. KBI Biopharma

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. AGC Biologics

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. SE Thermo Fisher (Patheon)

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. LakePharma

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Genscript Biotech Corporation

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Bionova Scientific

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Boehringer Ingelheim BioXcellence

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

    • 9.11. STC Biologics, Inc.

      • 9.11.1. Company Overview

      • 9.11.2. Key Executives

      • 9.11.3. Company Snapshot

      • 9.11.4. Operating Business Segments

      • 9.11.5. Product Portfolio

      • 9.11.6. Business Performance

      • 9.11.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET FOR MICROBIAL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET FOR MAMMALIAN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET FOR CELL LINE DEVELOPMENT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET FOR PROCESS DEVELOPMENT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET FOR ONCOLOGY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET FOR HEMATOLOGICAL DISORDERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 18. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 19. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 20. U.S. BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 21. U.S. BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 22. U.S. BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 23. CANADA BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 24. CANADA BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 25. CANADA BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 26. MEXICO BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 27. MEXICO BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 28. MEXICO BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 29. EUROPE BIOLOGICS CONTRACT DEVELOPMENT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 30. EUROPE BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 31. EUROPE BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 32. EUROPE BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 33. FRANCE BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 34. FRANCE BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 35. FRANCE BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 36. GERMANY BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 37. GERMANY BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 38. GERMANY BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 39. ITALY BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 40. ITALY BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 41. ITALY BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 42. SPAIN BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 43. SPAIN BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 44. SPAIN BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 45. UK BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 46. UK BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 47. UK BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 48. RUSSIA BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 49. RUSSIA BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 50. RUSSIA BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 51. REST OF EUROPE BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 52. REST OF EUROPE BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 53. REST OF EUROPE BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 54. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 55. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 56. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 57. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 58. CHINA BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 59. CHINA BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 60. CHINA BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 61. JAPAN BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 62. JAPAN BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 63. JAPAN BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 64. INDIA BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 65. INDIA BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 66. INDIA BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 67. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 68. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 69. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 70. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 71. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 72. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 73. THAILAND BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 74. THAILAND BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 75. THAILAND BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 76. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 77. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 78. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 79. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 80. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 81. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 84. REST OF ASIA PACIFIC BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 85. LAMEA BIOLOGICS CONTRACT DEVELOPMENT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 86. LAMEA BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 87. LAMEA BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 88. LAMEA BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 89. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 90. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 91. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 92. SOUTH AFRICA BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 93. SOUTH AFRICA BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 94. SOUTH AFRICA BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 95. SAUDI ARABIA BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 96. SAUDI ARABIA BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 97. SAUDI ARABIA BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 98. UAE BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 99. UAE BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 100. UAE BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 101. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 102. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 103. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 104. REST OF LAMEA BIOLOGICS CONTRACT DEVELOPMENT, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 105. REST OF LAMEA BIOLOGICS CONTRACT DEVELOPMENT, BY PRODUCT SERVICE, 2025-2033 ($MILLION)
  • TABLE 106. REST OF LAMEA BIOLOGICS CONTRACT DEVELOPMENT, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 107. WUXI BIOLOGICS: KEY EXECUTIVES
  • TABLE 108. WUXI BIOLOGICS: COMPANY SNAPSHOT
  • TABLE 109. WUXI BIOLOGICS: OPERATING SEGMENTS
  • TABLE 110. WUXI BIOLOGICS: PRODUCT PORTFOLIO
  • TABLE 111. WUXI BIOLOGICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. ABZENA LTD.: KEY EXECUTIVES
  • TABLE 113. ABZENA LTD.: COMPANY SNAPSHOT
  • TABLE 114. ABZENA LTD.: OPERATING SEGMENTS
  • TABLE 115. ABZENA LTD.: PRODUCT PORTFOLIO
  • TABLE 116. ABZENA LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. FUJIFILM DIOSYNTH BIOTECHNOLOGIES: KEY EXECUTIVES
  • TABLE 118. FUJIFILM DIOSYNTH BIOTECHNOLOGIES: COMPANY SNAPSHOT
  • TABLE 119. FUJIFILM DIOSYNTH BIOTECHNOLOGIES: OPERATING SEGMENTS
  • TABLE 120. FUJIFILM DIOSYNTH BIOTECHNOLOGIES: PRODUCT PORTFOLIO
  • TABLE 121. FUJIFILM DIOSYNTH BIOTECHNOLOGIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 122. KBI BIOPHARMA: KEY EXECUTIVES
  • TABLE 123. KBI BIOPHARMA: COMPANY SNAPSHOT
  • TABLE 124. KBI BIOPHARMA: OPERATING SEGMENTS
  • TABLE 125. KBI BIOPHARMA: PRODUCT PORTFOLIO
  • TABLE 126. KBI BIOPHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 127. AGC BIOLOGICS: KEY EXECUTIVES
  • TABLE 128. AGC BIOLOGICS: COMPANY SNAPSHOT
  • TABLE 129. AGC BIOLOGICS: OPERATING SEGMENTS
  • TABLE 130. AGC BIOLOGICS: PRODUCT PORTFOLIO
  • TABLE 131. AGC BIOLOGICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 132. SE THERMO FISHER (PATHEON): KEY EXECUTIVES
  • TABLE 133. SE THERMO FISHER (PATHEON): COMPANY SNAPSHOT
  • TABLE 134. SE THERMO FISHER (PATHEON): OPERATING SEGMENTS
  • TABLE 135. SE THERMO FISHER (PATHEON): PRODUCT PORTFOLIO
  • TABLE 136. SE THERMO FISHER (PATHEON): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 137. LAKEPHARMA: KEY EXECUTIVES
  • TABLE 138. LAKEPHARMA: COMPANY SNAPSHOT
  • TABLE 139. LAKEPHARMA: OPERATING SEGMENTS
  • TABLE 140. LAKEPHARMA: PRODUCT PORTFOLIO
  • TABLE 141. LAKEPHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 142. GENSCRIPT BIOTECH CORPORATION: KEY EXECUTIVES
  • TABLE 143. GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT
  • TABLE 144. GENSCRIPT BIOTECH CORPORATION: OPERATING SEGMENTS
  • TABLE 145. GENSCRIPT BIOTECH CORPORATION: PRODUCT PORTFOLIO
  • TABLE 146. GENSCRIPT BIOTECH CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 147. BIONOVA SCIENTIFIC: KEY EXECUTIVES
  • TABLE 148. BIONOVA SCIENTIFIC: COMPANY SNAPSHOT
  • TABLE 149. BIONOVA SCIENTIFIC: OPERATING SEGMENTS
  • TABLE 150. BIONOVA SCIENTIFIC: PRODUCT PORTFOLIO
  • TABLE 151. BIONOVA SCIENTIFIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 152. BOEHRINGER INGELHEIM BIOXCELLENCE: KEY EXECUTIVES
  • TABLE 153. BOEHRINGER INGELHEIM BIOXCELLENCE: COMPANY SNAPSHOT
  • TABLE 154. BOEHRINGER INGELHEIM BIOXCELLENCE: OPERATING SEGMENTS
  • TABLE 155. BOEHRINGER INGELHEIM BIOXCELLENCE: PRODUCT PORTFOLIO
  • TABLE 156. BOEHRINGER INGELHEIM BIOXCELLENCE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 157. STC BIOLOGICS, INC.: KEY EXECUTIVES
  • TABLE 158. STC BIOLOGICS, INC.: COMPANY SNAPSHOT
  • TABLE 159. STC BIOLOGICS, INC.: OPERATING SEGMENTS
  • TABLE 160. STC BIOLOGICS, INC.: PRODUCT PORTFOLIO
  • TABLE 161. STC BIOLOGICS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SEGMENTATION
  • FIGURE 2. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET
  • FIGURE 3. SEGMENTATION BIOLOGICS CONTRACT DEVELOPMENT MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN BIOLOGICS CONTRACT DEVELOPMENT MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALBIOLOGICS CONTRACT DEVELOPMENT MARKET
  • FIGURE 11. BIOLOGICS CONTRACT DEVELOPMENT MARKET SEGMENTATION, BY BY SOURCE
  • FIGURE 12. BIOLOGICS CONTRACT DEVELOPMENT MARKET FOR MICROBIAL, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. BIOLOGICS CONTRACT DEVELOPMENT MARKET FOR MAMMALIAN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. BIOLOGICS CONTRACT DEVELOPMENT MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. BIOLOGICS CONTRACT DEVELOPMENT MARKET SEGMENTATION, BY BY PRODUCT SERVICE
  • FIGURE 16. BIOLOGICS CONTRACT DEVELOPMENT MARKET FOR CELL LINE DEVELOPMENT, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. BIOLOGICS CONTRACT DEVELOPMENT MARKET FOR PROCESS DEVELOPMENT, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. BIOLOGICS CONTRACT DEVELOPMENT MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. BIOLOGICS CONTRACT DEVELOPMENT MARKET SEGMENTATION, BY BY DISEASE INDICATION
  • FIGURE 20. BIOLOGICS CONTRACT DEVELOPMENT MARKET FOR ONCOLOGY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. BIOLOGICS CONTRACT DEVELOPMENT MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. BIOLOGICS CONTRACT DEVELOPMENT MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. BIOLOGICS CONTRACT DEVELOPMENT MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. BIOLOGICS CONTRACT DEVELOPMENT MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 26. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 27. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 28. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 29. COMPETITIVE DASHBOARD
  • FIGURE 30. COMPETITIVE HEATMAP: BIOLOGICS CONTRACT DEVELOPMENT MARKET
  • FIGURE 31. TOP PLAYER POSITIONING, 2024
  • FIGURE 32. WUXI BIOLOGICS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 33. WUXI BIOLOGICS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 34. WUXI BIOLOGICS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 35. ABZENA LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 36. ABZENA LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 37. ABZENA LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 38. FUJIFILM DIOSYNTH BIOTECHNOLOGIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 39. FUJIFILM DIOSYNTH BIOTECHNOLOGIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 40. FUJIFILM DIOSYNTH BIOTECHNOLOGIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 41. KBI BIOPHARMA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 42. KBI BIOPHARMA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 43. KBI BIOPHARMA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 44. AGC BIOLOGICS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 45. AGC BIOLOGICS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 46. AGC BIOLOGICS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 47. SE THERMO FISHER (PATHEON): NET SALES, 2022-2024 ($MILLION)
  • FIGURE 48. SE THERMO FISHER (PATHEON): REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 49. SE THERMO FISHER (PATHEON): REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 50. LAKEPHARMA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 51. LAKEPHARMA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 52. LAKEPHARMA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 53. GENSCRIPT BIOTECH CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 54. GENSCRIPT BIOTECH CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 55. GENSCRIPT BIOTECH CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 56. BIONOVA SCIENTIFIC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 57. BIONOVA SCIENTIFIC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 58. BIONOVA SCIENTIFIC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 59. BOEHRINGER INGELHEIM BIOXCELLENCE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 60. BOEHRINGER INGELHEIM BIOXCELLENCE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 61. BOEHRINGER INGELHEIM BIOXCELLENCE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 62. STC BIOLOGICS, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 63. STC BIOLOGICS, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 64. STC BIOLOGICS, INC.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Biologics Contract Development Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved